Indoco Remedies is currently trading at Rs 343.20, up by 13.75 points or 4.17% from its previous closing of Rs 329.45 on the BSE.
The scrip opened at Rs. 330.00 and has touched a high and low of Rs. 349.00 and Rs. 329.00 respectively. So far 15832 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 360.35 on 07-Sep-2016 and a 52 week low of Rs. 244.00 on 25-Feb-2016.
Last one week high and low of the scrip stood at Rs. 349.00 and Rs. 310.00 respectively. The current market cap of the company is Rs. 3169.51 crore.
The promoters holding in the company stood at 59.24%, while Institutions and Non-Institutions held 20.71% and 20.05% respectively.
Indoco Remedies has acquired the manufacturing facility located at Baddi of Micro Labs, a Bangalore based company. The facility is spread over an area of 18000sq.mt, out of which 11,000sq.mt.is the built-up area. It produces 4.3 billion tablets and 50 million capsules p.a.
The acquired manufacturing site is close to the company’s existing manufacturing plant in Baddi, Himachal Pradesh. Baddi will thus be another manufacturing hub for the company’s solid dosages business in the regulated markets.
With this acquisition, Indoco will now have 6 facilities for finished dosages and 3 for active pharmaceutical ingredients (APIs). Out of these, 3 facilities for finished dosages, including sterile plant and 2 facilities for API manufacturing are USFDA approved.
Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: